Although anti-VEGF/VEGFR therapies have demonstrated potent inhibition of angiogenesis and tumor growth in preclinical models5,6, accumulating clinical data have shown that VEGF-targeted therapies do not benefit all cancer patients and can lead to serious adverse side effects7–9. The gene discussed is VEGFA; the disease is cancer.